kjh The Korean Journal of Hematology Korean J Hematol 1738-7949 2092-9129 Korean Society of Hematology 10.5045/kjh.2008.43.1.1 kjh-43-1 Review Article The Strategies for the Prevention of Chronic GVHD in Hematopoietic Stem Cell Transplantation LeeJong-WookM.D., Ph.D. Division of Hematology, Department of Internal Medicine, Catholic Hematopoietic Stem Cell Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Korea Correspondence to：Jong-Wook Lee, M.D., Ph.D. Division of Hematology, Department of Internal Medicine, St. Mary's Hospital, College of Medicine, The Catholic University of Korea 62, Yeouido-dong, Yeoungdeungpo-gu, Seoul 150-713, Korea Tel: ＋82-2-3779-1037, Fax: ＋82-2-780-3132 E-mail: jwlee@catholic.ac.kr 32008 1932008 4311 8 24032008 25032008 27032008 Copyright © 2008 Korean Society of Hematology 2008 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chronic graft-versus-host disease (GVHD) is the most frequent late complication after hematopoietic cell transplantation and has a major impact on the quality of life and survival. As the pathophysiology of GVHD is still incompletely understood, it has been difficult to design effective prophylactic regimens. However, prevention of acute GVHD appears to result in a lower incidence of chronic GVHD. The use of younger, non-allo-sensitized donors, preferentially of the same sex as the patient, and the use of stem cells other than G-CSF-mobilized peripheral blood stem cells, are associated with a decreased frequency of chronic GVHD. Further, the incorporation of thymoglobulin into the conditioning regimen has been demonstrated as beneficial to reduce chronic GVHD and delayed complications.

 Chronic GVHD Prevention Hematopoietic cell transplantation REFERENCESDuell T van Lint MT Ljungman P Health and functional status of long-term survivors of bone marrow transplantation. EBMT working party on late effects and EULEP Study group on late effects. European group of blood and marrow transplantation Ann Intern Med 1997126 18492 Deeg HJ Leisenring W Storb R Long-term outcome after marrow transplantation for severe aplastic anemia Blood 199891 363745 Glucksberg H Storb R Fefer A Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors Transplantation 197418 295304 Mielcarek M Martin PJ Leisenring W Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation Blood 2003102 75662 Mielcarek M Burroughs L Leisenring W Prognostic relevance of “early-onset” graft-versus-host disease following nonmyeloablative hematopoietic cell transplantation Br J Haematol 2005129 38191 Filipovich AH Weisdorf D Pavletic S National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report Biol Blood Marrow Transplant 200511 94556 Hess AD Jones RJ Autologous graft-versus-host disease Thomas ED Blume KG Forman SJ Hematopoietic cell transplantation 2nd ed. Boston Blackwell Science 1999 3428 Storb R Prentice RL Buckner CD Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment N Engl J Med 1983308 3027 Cutler C Giri S Jeyapalan S Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis J Clin Oncol 200119 368591 Zaucha JM Gooley T Bensinger WI CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation Blood 200198 32217 Wagner JE Barker JN Defor TE Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival Blood 2002100 16118 Sullivan KM Agura E Anasetti C Chronic graft-versus-host disease and other late complications of bone marrow transplantation Semin Hematol 199128 2509 Remberger M Aschan J Lönnqvist B An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation Eur J Haematol 200166 506 Oh H Loberiza FR Jr Zhang MJ Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations Blood 2005105 140816 Randolph SSB Gooley TA Warren EH Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic cell transplants Blood 2004103 34752 Miklos DB Kim HT Miller KH Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission Blood 2005105 29738 Holmes JA Whittaker JA Histocompatibility antigen DR4 is associated with chronic graft-versus-host disease in the south Wales population Br J Haematol 198973 424 Pawelec G Müller CA Haen M Ehninger G Chronic graft-versus-host disease and HLA-DR4 in the southern German population Br J Haematol 199075 2956 Kim HJ Park SJ Im HW The association of HLA antigen and GVHD in allogeneic hemopoietic stem cell transplantation with histocompatible sibling donor: a single-center experience in Korea Int J Hematol 200276 26771 Ho VT Mirza NQ Junco Dd D Okamura T Prze-piorka D The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis Bone Marrow Transplant 200332 7715 Jenkins MK Schwartz RH Pardoll DM Effects of cyclosporine A on T cell development and clonal deletion Science 1988241 16558 Sakoda Y Hashimoto D Asakura S Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease Blood 2007109 175664 Zhang C Todorov I Zhang Z Donor CD4＋ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations Blood 2006107 29933001 Kansu E The pathophysiology of chronic graft-versus-host disease Int J Hematol 200479 20915 Alpdogan O Schmaltz C Muriglan SJ Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease Blood 200198 225665 Alpdogan O Muriglan SJ Eng JM IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation J Clin Invest 2003112 1095107 Sinha ML Fry TJ Fowler DH Miller G Mackall CL Interleukin 7 worsens graft-versus-host disease Blood 2002100 26429 Chung B Dudl E Toyama A IL-7 is necessary for induction of experimental graft-versus-host disease (GVHD) Blood 2003102 149a, #514. Weinberg K Blazar BR Wagner JE Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation Blood 200197 145866 Seggewiss R Einsele H Hematopoietic growth factors including keratinocyte growth factor in allogeneic and autologous stem cell transplantation Semin Hematol 200744 20311 Lee SJ New approaches for preventing and treating chronic graft-versus-host disease Blood 2005105 42006 Ruggeri L Capanni M Urbani E Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 2002295 2097100 Chan GW Foss FM Klein AK Sprague K Miller KB Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease Biol Blood Marrow Transplant 20039 7539 Chao NJ Parker PM Niland JC Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease Biol Blood Marrow Transplant 19962 8692 Sokos DR Berger M Lazarus HM Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation Biol Blood Marrow Transplant 20028 11730 Kansu E Gooley T Flowers ME Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial Blood 200198 386870 Soiffer RJ Martin P T-cell depletion of allogeneic hematopoietic stem cell grafts Atkinson K Champlin R Ritz J, Clinical bone marrow and blood stem cell transplantation 3rd ed. Cambridge, UK Cambridge University Press 2004 41625 Wagner JE Thompson JS Carter SL Kernan NA Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial Lancet 2005366 73341 Kottaridis PD Milligan DW Chopra R In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation Blood 200096 241925 Soiffer RJ Weller E Alyea EP CD6＋ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors J Clin Oncol 200119 11529 Bacigalupo A Lamparelli T Bruzzi P Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO) Blood 200198 29427 Bacigalupo A Lamparelli T Barisione G Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation Biol Blood Marrow Transplant 200612 5605 Remberger M Svahn BM Mattsson J Ringdén O Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation Transplantation 200478 1227 Remberger M Svahn BM Hentschke P Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation Bone Marrow Transplant 199924 82330 Deeg HJ Storer BE Boeckh M Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen Biol Blood Marrow Transplant 200612 57384 Schetelig J Bornhäuser M Kiehl M Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation—a retrospective analysis Bone Marrow Transplant 200433 48390 Kim HJ Min WS Eom KS Anti-leukemic role of acute GVHD after unrelated haematopoietic stem cell transplantation in intermediate- to high-risk acute myelogenous leukemia Bone Marrow Transplant 200740 106974 Lopez M Clarkson MR Albin M A novel mechanism of action for anti-thymocyte globulin: induction of CD4＋CD25＋Foxp3＋ regulatory T cells J Am Soc Nephrol 200617 284453 Maury S Mary JY Rabian C Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients Br J Haematol 2001115 63041 Cutler C Miklos D Kim HT Rituximab for steroid-refractory chronic graft-versus-host disease Blood 2006108 75662 Stewart BL Storer B Storek J Duration of immunosuppressive treatment for chronic graft-versus-host disease Blood 2004104 35016 Akpek G Lee SJ Flowers ME Performance of a new clinical grading system for chronic graft-versus-host disease: a multi-center study Blood 2003102 8029 Lee SJ Vogelsang G Flowers ME Chronic graft-versus-host disease Biol Blood Marrow Transplant 20039 21533 Couriel D Carpenter PA Cutler C Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary therapy and supportive care working group report Biol Blood Marrow Transplant 200612 37596